ALEXANDRIA, Va., June 5 -- United States Patent no. 12,275,789, issued on April 15, was assigned to NBE-Therapeutics AG (Basel, Switzerland).
"Human antibodies binding to ROR2" was invented by Ulf Grawunder (Hersberg, Switzerland), Roger Beerli (Adlikon bei Regensdorf, Switzerland), Ina Hellmann (Huningue, France) and Lorenz Waldmeier (Basel, Switzerland).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to fully human antibodies and conjugates thereof, which specifically bind to the extracellular domain of receptor tyrosine kinase-like orphan receptor 2 (ROR2)."
The patent was filed on July 22, 2022, under Application No. 17/814,488.
*For further information, including images, ch...